Gut Bacteria May Be Undermining Key Parkinson’s Therapy, Study Warns

A new study has raised concerns over a previously overlooked factor that could be quietly affecting the effectiveness of treatment for Parkinson’s disease—the human gut microbiome.

Researchers have found that commonly prescribed drugs known as catechol-O-methyltransferase inhibitors (COMT inhibitors), routinely used alongside levodopa, may alter gut bacteria in ways that reduce the availability of the drug to the brain. The findings, published in the journal Nature Microbiology, suggest that the interaction between medicines and microbes could have significant implications for patient outcomes.

Levodopa remains the gold-standard therapy for Parkinson’s disease, as it is converted into dopamine—a neurotransmitter that is deficient in patients and responsible for controlling movement. To enhance its effectiveness, doctors often prescribe COMT inhibitors, which are designed to prevent the breakdown of levodopa before it reaches the brain.

However, the new research suggests that this combination may have unintended consequences.

The study indicates that COMT inhibitors can selectively suppress certain gut bacteria while allowing others to thrive. Among those that may increase are species belonging to the Enterococcus group—microbes already known to possess enzymes capable of breaking down levodopa in the intestine.

This means that even before the drug enters the bloodstream, a portion of it may be degraded in the gut, reducing the amount that ultimately reaches the brain where it is needed most.

Scientists warn that this microbial interference could partly explain why some patients experience fluctuations in response to treatment, despite receiving standard drug combinations. In effect, the gut may be acting as an unrecognized gatekeeper, determining how much of the medication is actually available for therapeutic action.

“This is a striking example of how gut bacteria can influence the way drugs behave in the body,” the researchers noted, adding that such interactions have largely been overlooked in conventional drug studies.

Traditionally, drug interactions have been studied in the context of human enzymes, particularly those in the liver. But the human body also hosts trillions of microorganisms, many of which produce their own enzymes capable of modifying drugs—especially those taken orally.

The findings highlight what scientists are now calling a “drug–microbiome–drug interaction,” where one medication alters the microbial environment in a way that affects the metabolism of another.

Experts say this could have wider implications beyond Parkinson’s disease. Patients with chronic illnesses often take multiple medications, and similar interactions may be occurring without being fully understood.

For Parkinson’s patients, the implications are particularly significant. The disease is progressive and requires precise management of symptoms. Even small reductions in drug availability can translate into worsening tremors, stiffness, or impaired mobility.

The study does not suggest that patients should stop taking COMT inhibitors, but it underscores the need for more personalized approaches to treatment.

Researchers emphasize that further studies are needed to understand the full clinical impact and to explore whether modifying gut bacteria—through diet, probiotics, or targeted therapies—could improve drug effectiveness.

The findings also open up a new frontier in medicine, where the microbiome becomes an essential factor in prescribing decisions.

With Parkinson’s cases rising globally, including in India, the research serves as a reminder that effective treatment may depend not only on the drugs prescribed, but also on the complex ecosystem within the human body.